829 related articles for article (PubMed ID: 18923406)
1. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
2. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
3. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.
Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG
Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416
[TBL] [Abstract][Full Text] [Related]
6. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
Nolan D
Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
[TBL] [Abstract][Full Text] [Related]
7. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics in drug development.
McCarthy AD; Kennedy JL; Middleton LT
Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
[TBL] [Abstract][Full Text] [Related]
9. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
Otsubo Y
Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
Nolan D; Gaudieri S; Mallal S
J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
[TBL] [Abstract][Full Text] [Related]
12. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
[TBL] [Abstract][Full Text] [Related]
13. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
14. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
16. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic biomarkers for predicting drug response.
Bank PC; Swen JJ; Guchelaar HJ
Expert Rev Mol Diagn; 2014 Jul; 14(6):723-35. PubMed ID: 24857685
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of drug hypersensitivity.
Phillips EJ; Mallal SA
Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics to predict drug-related adverse events.
Hosford DA; Lai EH; Riley JH; Xu CF; Danoff TM; Roses AD
Toxicol Pathol; 2004; 32 Suppl 1():9-12. PubMed ID: 15209398
[TBL] [Abstract][Full Text] [Related]
20. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
Bienfait KL; Shaw PM; Murthy G; Warner AW
Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
